Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.40 |
| ▸ | ACACA | Q13085 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133300 | 0.85 | ACACB (0.43) | ACACBACACAHPGDLMNAALDH1A1 | |
| SCHEMBL23350139 | 0.84 | ACACB (0.42) | ACACBACACAHPGDLMNAALDH1A1 | |
| SCHEMBL18592240 | 0.84 | HPGD (0.43) | ACACBACACAHPGDLMNAALDH1A1 | |
| SCHEMBL24654315 | 0.83 | ACACB (0.44) | ACACBACACAHPGDLMNA | |
| SCHEMBL21906681 | 0.82 | ACACB (0.40) | ACACBACACAHPGDLMNAALDH1A1 | |
| SCHEMBL21898966 | 0.81 | EPHX2 (0.39) | ALDH1A1GAA | |
| SCHEMBL20330249 | 0.81 | ACACB (0.40) | ACACBACACAHPGDLMNAALDH1A1 | |
| SCHEMBL20325828 | 0.78 | CYP4F2 (0.34) | LMNAALDH1A1 | |
| SCHEMBL24935185 | 0.78 | KMT2A (0.50) | — | |
| SCHEMBL20046548 | 0.77 | APP (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ACACB 1442/4885ACACA 1830/4885HPGD 3091/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ACACB 1442/4885ACACA 1830/4885HPGD 3091/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | ACACB 1442/4885ACACA 1830/4885HPGD 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.